DOCSLIB.ORG

MRSA, a Worldwide Problem …

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MRSA, a Worldwide Problem … S. aureus: what do we need to know (and to do) in 2007 ? The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, …): is the future (really) shining ? Françoise Van Bambeke Unité de Pharmacologie cellulaire et moléculaire Université catholique de Louvain Bruxelles, Belgium http://www.facm.ucl.ac.be Sympo – S. aureus – 11/01/07 - 1 do we need new drugs ? Sympo – S. aureus – 11/01/07 - 2 « old » antibiotics: still usable for CA-MRSA ! Rice, Am. J. Med. (2006) 119:S11-9 Sympo – S. aureus – 11/01/07 - 3 « old » antibiotics: still usable for CA-MRSA ! Sabol et al., Ann. Pharmacother. (2006) 40:1125-33 Sympo – S. aureus – 11/01/07 - 4 recent and novel agents for S. aureus recently on the market; (late) stage of brought on the not yet clinical investigational Belgian market in Belgium development moxifloxacin synercid telavancin CS-023/PZ-601 linezolid daptomycin oritavancin MX-2401 tigecycline dalbavancin API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK-771 ... What will be your choice ? Sympo – S. aureus – 11/01/07 - 5 recent and novel agents for S. aureus recently on the market; (late) stage of brought on the not yet clinical investigational Belgian market in Belgium development moxifloxacin synercid telavancin CS-023/PZ-601 linezolid daptomycin oritavancin MX-2401 tigecycline dalbavancin API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK-771 ... Let’s try to find a way … Sympo – S. aureus – 11/01/07 - 6 recent and novel agents for S. aureus recently on the market; (late) stage of brought on the not yet clinical investigational Belgian market in Belgium development moxifloxacin synercid telavancin CS-023/PZ-601 linezolid daptomycin oritavancin MX-2401 tigecycline dalbavancin API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK-771 ... Sympo – S. aureus – 11/01/07 - 7 moxifloxacin and CA-MRSA killing curves - 6 CA-MRSA 0 clindamycin linezolid -1 minocycline rifampicin -2 log CFU/ml Δ -3 sulfametoxazole moxifloxacin 0 6 12 18 24 time (h) rap b idly act eric idal Kaka et al., JAC (2006) 58:680-3 Sympo – S. aureus – 11/01/07 - 8 moxifloxacin: in vitro data Distribution of MICs for 100 MRSA collected in 2002 breakpoint 60 S R cipro 50 levo Lowest MICs moxi among currently 40 available 30 quinolones, 20 but … 10 percentage of strains 0 4 8 1 2 16 32 64 0.5 128 256 0.25 MIC (mg/L) low level high level resistance resistance Noguchi et al., Int. J. Antimicrob. Ag. (2005) 25:374-9 Sympo – S. aureus – 11/01/07 - 9 moxifloxacin: pros and cons • rapidly bactericidal • cross resistance with • easy switch iv-po other quinolones • once-a-day even if MIC lower • no major toxicity issue Æ CA-MRSA only (already quite large • risk of Ê QTc interval clinical experience) (drug interactions !) Sympo – S. aureus – 11/01/07 - 10 recent and novel agents for S. aureus recently on the market; (late) stage of brought on the not yet clinical investigational Belgian market in Belgium development moxifloxacin synercid telavancin CS-023/PZ-601 linezolid daptomycin oritavancin MX-2401 tigecycline dalbavancin API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK-771 ... Sympo – S. aureus – 11/01/07 - 11 linezolid O HN O N N O F O • inhibits the formation of the initiation complex • no cross resistance with other drugs acting on protein synthesis (MLS) • resistance considered for long as improbable … but now well described (due to mutations in 23S rRNA) Bozdogan & Appelbaum, Int. J. Antimicrob. Ag. (2004) 23:113-9 Sympo – S. aureus – 11/01/07 - 12 linezolid: in vitro data Distribution of MICs for 60 MRSA collected from diabetic foot drug range MIC 50 MIC 90 breakpoint vancomycin 0.5-1 0.5 1 8 linezolid 2-8 4 4 4 We slowly reach the limit … Goldstein et al., AAC (2006) 50:2875-79 Sympo – S. aureus – 11/01/07 - 13 linezolid: in vitro data Susceptibility of MRSA by site of isolation 8 4 breakpoint again we approach the limit … Wilson et al., JAC (2006) 58:470-3 Sympo – S. aureus – 11/01/07 - 14 linezolid: clinical experience indication Linezolid Vancomycin 600 mg iv/po 1g iv 2x/day 2x/day cSSTI (1180) 99.2 % 88.5 % Osteomyelitis (66) 84.8 % -- MRSA bacteriaemia (53) 56 % 46 % nosocomial pneumonia (1019) 53 % 52.2 % MRSA (160) 59 % 35.5 % Weigelt et al., AAC (2005) 49:2260-66; Senneville et al., Clin Ther. (2006) 28:1155-63; Shorr et al., JAC (2005) 56:923-929; Wunderink et al., Chest (2003)124:1789-97 Sympo – S. aureus – 11/01/07 - 15 linezolid: pros and cons • excellent biodisponibility • bacteriostatic and tissue penetration • resistance already selected • easy switch iv-po • high price • twice-a-day • serious side effects (myelosuppression) • drug interactions (IMAO) Sympo – S. aureus – 11/01/07 - 16 recent and novel agents for S. aureus recently on the market; (late) stage of brought on the not yet clinical investigational Belgian market in Belgium development moxifloxacin synercid telavancin CS-023/PZ-601 linezolid daptomycin oritavancin MX-2401 tigecycline dalbavancin API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK-771 ... Sympo – S. aureus – 11/01/07 - 17 synercid SA blocks peptide bound formation dalfopristin SYNERGY quinupristin SB blocks the path of the nascent peptide Harms et al., BMB Biol (2004) 2:4 Sympo – S. aureus – 11/01/07 - 18 synercid: in vitro data Susceptibility of 101 MRSA breakpoint 60 S R 50 40 30 20 10 percentage of strains of percentage 0 1 2 0.5 0.25 0.06 0.03 0.125 0.015 0.0625 What about these ? 0.03125 0.015625 MIC (mg/L) Sambatakou et al., JAC (1998) 51:349-55 Sympo – S. aureus – 11/01/07 - 19 synercid: in vitro data In vitro models - MRSA 3 5 h 24h 2 1 0 -1 -2 log CFU from time 0 time from CFU log Δ -3 -4 -2 -1 0 1 2 MIC Cmax Log concentration (mg/L) time- and concentration-dependent bactericidal effect Baudoux et al., ECCMID (2007) Sympo – S. aureus – 11/01/07 - 20 synercid: in vitro data In vitro pharmacodynamic models • poorly active alone against MRSA; highly active on VRE • combinations synergistic towards MRSA Allen et al., AAC (2002) 46:2606-12 Sympo – S. aureus – 11/01/07 - 21 synercid : pros and cons • highly active on VRE • poorly bactericidal • synergistic in vitro against MRSA with many ABs • bid or tid administration • no oral route • cross-resistance with ML • drug interactions (CYP450 3A4) caution with drugs prolonging QTc • myalgia/arthralgia frequent • high price • not studied in children Sympo – S. aureus – 11/01/07 - 22 recent and novel agents for S. aureus recently on the market; (late) stage of brought on the not yet clinical investigational Belgian market in Belgium development moxifloxacin synercid telavancin CS-023/PZ-601 linezolid daptomycin oritavancin MX-2401 tigecycline dalbavancin API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK-771 ... Sympo – S. aureus – 11/01/07 - 23 daptomycin • very bactericidal towards Gram (+) organisms through membrane destabilization • spare mammalian cells because they lack phosphatidylglycerol (critical for binding to Gram(+) membranes) • fast track registration in the US because of activity against vancomycin-resistant enterococci (VRE) • indications: cSSTI; Phase III trial on bacteriemia completed Sympo – S. aureus – 11/01/07 - 24 daptomycin: in vitro data Distribution of MICs for 60 MRSA collected from diabetic foot drug range MIC 50 MIC 90 breakpoint vancomycin 0.5-1 0.5 1 8 daptomycin 0.25-1 0.5 0.5 1 wait and see … Goldstein et al., AAC (2006) 50:2875-79 Sympo – S. aureus – 11/01/07 - 25 daptomycin: clinical experience indication Daptomycin Vancomycin iv 1x/day or β-lactam cSSTI (902) 4 mg/kg 83.4 % 84.2 % MRSA (28-36) 75 % 69.4 % bloodstream (31) 6 mg/kg 77 % -- MRSA (11) 100 % VRE (11) 45 % Arbeit et al., CID (2004) 38:1673-81; Segreti et al., Pharmacotherapy (2006) 26:347-352 Sympo – S. aureus – 11/01/07 - 26 daptomycin: pros and cons • rapidly bactericidal • inactive in pneumonia • once-a-day • VISA tend to have Ê MICs • high price • no oral route • musculotoxic in animals avoid combination with inhibitors of HMGCoA reductase • safety / efficacy not studied in < 18 years Sympo – S. aureus – 11/01/07 - 27 recent and novel agents for S. aureus recently on the market; (late) stage of brought on the not yet clinical investigational Belgian market in Belgium development moxifloxacin synercid telavancin CS-023/PZ-601 linezolid daptomycin oritavancin MX-2401 tigecycline dalbavancin API-1252 ceftobiprole DK-619 iclaprim new oxazolidinones retapamulin new ketolides WCK-771 ... Sympo – S. aureus – 11/01/07 - 28 tigecycline tigecycline • same binding site as tetracyclines in ribosome 16S RNA; additional interaction site tetracycline • Unaffected by resistance due to minocycline - ribosomal protection - Tet efflux pumps • Approved in USA in 2005 and in Europe in 2006 • wide spectrum, indicated for: cSSTI; intra-abdominal infections Olson et al., AAC (2006) 50:2156-66 Sympo – S. aureus – 11/01/07 - 29 tigecycline: in vitro data Distribution of MICs for 128 MRSA from USA breakpoint 80 S R tigecycline minocycline active 60 on minocycline-R population, but … 40 20 percentage of strains of percentage 0 1 2 4 8 16 32 64 0.5 128 256 0.25 0.125 MIC (mg/L) a few isolates above the breakpoint … Low et al., Int. J. Antimicrob. Ag. (2002) 20:220-2 Sympo – S. aureus – 11/01/07 - 30 tigecycline clinical experience Phase 3 - Skin and skin structure infections Ellis-Grosse et al., Clin. Infect. Dis. (2005) 41:S341-53 Sympo – S.
Load more

Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • 9-20-08 Referral
    Comparative studies with antibiotics: Why should we change the rules? Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium 10-10-2012 Late Phase Leaders Forum, Vienna, Austria 1 What its all about ? • We are in real need of novel antibiotics… but … most clinical studies with new compounds aim at equivalence or non-inferiority, failing to meet clinicians’ expectations and regulatory requirements for novelty. In parallel, safety issues are becoming an increasingly worrying hurdle for manufacturers Pricing make antibiotic unattractive • What are the possible solutions ? 10-10-2012 Late Phase Leaders Forum, Vienna, Austria 2 The antibiotic crisis * * A pictorial view using 4 paintings of Van Gogh (who stayed briefly in Belgium when moving from Holland to France) and with selected Belgian and International data… 10-10-2012 Late Phase Leaders Forum, Vienna, Austria 3 Are antibiotics following a path to madness ? discovery in soil bacteria and fungi 1928 - … 10-10-2012 Late Phase Leaders Forum, Vienna, Austria 4 Are antibiotics following a path to madness ? and then we all saw the blooming tree of semi- synthetic and totally synthetic antibiotics 1950 – 1980 … 10-10-2012 Late Phase Leaders Forum, Vienna, Austria 5 Are antibiotics following a path to madness ? and the US General Surgeon told us that the fight was over 1970 … 10-10-2012 Late Phase Leaders Forum, Vienna, Austria 6 Are antibiotics following a path to madness ? But… 2012 … 10-10-2012 Late Phase Leaders Forum, Vienna, Austria 7 Extent of resistance of P.
    [Show full text]
  • An Updated Review of Iclaprim
    Open Forum Infectious Diseases REVIEW ARTICLE An Updated Review of Iclaprim: A Potent and Rapidly Bactericidal Antibiotic for the Treatment of Skin and Skin Structure Infections and Nosocomial Pneumonia Caused by Gram-Positive Including Multidrug-Resistant Bacteria David B. Huang,1 Catherine D. Strader,3 James S. MacDonald,3 Mark VanArendonk,2 Richard Peck,4 and Thomas Holland5 1Motif BioSciences, New York, New York; Rutgers New Jersey Medical School, 2Vermeer Pharma, Morristown, New Jersey, 3Synergy Partners R&D Solutions, Chester, New Jersey; 4Hemex, Liestal, Switzerland, 5Duke University Medical Center, Durham, North Carolina New antibiotics are needed because of the increased morbidity and mortality associated with multidrug-resistant bacteria. Iclaprim, a bacterial dihydrofolate reductase inhibitor, not currently approved, is being studied for the treatment of skin infections and noso- comial pneumonia caused by Gram-positve bacteria, including multidrug-resistant bacteria. Iclaprim showed noninferiority at –10% to linezolid in 1 of 2 phase 3 studies for the treatment of complicated skin and skin structure infections with a weight-based dose (0.8 mg/kg) but did not show noninferiority at –10% to linezolid in a second phase 3 study. More recently, iclaprim has shown noninferiority at –10% to vancomycin in 2 phase 3 studies for the treatment of acute bacterial skin and skin structure infections with an optimized fixed dose (80 mg). A phase 3 study for the treatment of hospital-acquired bacterial and ventilator-associated bacterial pneumonia is upcoming. If, as anticipated, iclaprim becomes available for the treatment of skin and skin structure infections, it will serve as an alternative to current antibiotics for treatment of severe infections.
    [Show full text]
  • Potent Late-Stage Antibiotic for Serious and Life-Threatening Bacterial
    ADVERTISEMENT FEATURE Motif BioSciences, Inc. www.motifbio.com Potent late-stage antibiotic for serious and life-threatening bacterial infections Motif Bio’s iclaprim shows rapid bactericidal activity and low propensity for induction of resistance and is in late-stage clinical testing for acute bacterial skin and skin structure infections. The need for new antibiotics to combat multidrug- a Control Vanco 8×MIC Iclaprim 2×MIC b resistant infections is increasingly urgent in the hos- 1.00E+101010 Induction of resistance with iclaprim and trimethoprim: Staphylococcus. aureus ATCC 25923 (trimethoprim sensitive).* pital setting, where patients often succumb to serious 1.00E+091090 and life-threatening infections that require immedi- 1.00E+081080 140 1.00E+071070 120 profile ate treatment with the best available antibiotic. 100 1.00E+061060 CFU 80 Motif Bio is a clinical-stage biopharmaceutical com- 1.00E+051050 60 40 MIC (mg/ml) pany developing new antibiotics against serious and 1.00E+0410 40 30 1.00E+0310 20 life-threatening infections caused by multidrug-resis- 20 1.00E+0210 0 tant bacteria. Its lead product candidate, iclaprim, is 00 0 5 10 15 20 25 10 Passage number 1.00E+010 being developed for the treatment of the most com- 0 1 2 3 4 5 6 7 8 9 10 Trimethoprim Iclaprim Rifampin mon and serious bacterial infections, such as acute Time (h) *Similar results were obtained with a trimethoprim-resistant (F98Y) S. aureus. bacterial skin and skin structure infections (ABSSSIs) and hospital-acquired bacterial pneumonia (HABP), Figure 1: Iclaprim bactericidal activity and low resistance profile.
    [Show full text]
  • The Effect of Pulmonary Surfactant on the in Vitro Activity of Iclaprim Against Common Respiratory Bacterial Pathogens
    ÅÒ The Effect of Pulmonary Surfactant on the In Vitro Activity of Iclaprim Against Common Respiratory Bacterial Pathogens David B Huang, Leonard R Duncan, Robert K Flamm, Matthew Dry- den, G. Ralph Corey, Mark H Wilcox, Antoni Torres, Thomas M File Jr PII: S0732-8893(17)30285-7 DOI: doi: 10.1016/j.diagmicrobio.2017.09.011 Reference: DMB 14429 To appear in: Diagnostic Microbiology and Infectious Disease Received date: 10 March 2017 Revised date: 23 June 2017 Accepted date: 16 September 2017 Please cite this article as: Huang David B, Duncan Leonard R, Flamm Robert K, Dryden Matthew, Corey G. Ralph, Wilcox Mark H, Torres Antoni, File Jr Thomas M, The Effect of Pulmonary Surfactant on the In Vitro Activity of Iclaprim Against Common Respiratory Bacterial Pathogens, Diagnostic Microbiology and Infectious Disease (2017), doi: 10.1016/j.diagmicrobio.2017.09.011 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT The Effect of Pulmonary Surfactant on the In Vitro Activity of Iclaprim Against Common Respiratory Bacterial Pathogens David B Huang,1 Leonard R Duncan,2 Robert K Flamm,2 Matthew Dryden,3 G. Ralph Corey,4 Mark
    [Show full text]
  • Antibacterial Prodrugs to Overcome Bacterial Resistance
    molecules Review Antibacterial Prodrugs to Overcome Bacterial Resistance Buthaina Jubeh , Zeinab Breijyeh and Rafik Karaman * Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem P.O. Box 20002, Palestine; [email protected] (B.J.); [email protected] (Z.B.) * Correspondence: [email protected] or rkaraman@staff.alquds.edu Academic Editor: Helen Osborn Received: 10 March 2020; Accepted: 26 March 2020; Published: 28 March 2020 Abstract: Bacterial resistance to present antibiotics is emerging at a high pace that makes the development of new treatments a must. At the same time, the development of novel antibiotics for resistant bacteria is a slow-paced process. Amid the massive need for new drug treatments to combat resistance, time and effort preserving approaches, like the prodrug approach, are most needed. Prodrugs are pharmacologically inactive entities of active drugs that undergo biotransformation before eliciting their pharmacological effects. A prodrug strategy can be used to revive drugs discarded due to a lack of appropriate pharmacokinetic and drug-like properties, or high host toxicity. A special advantage of the use of the prodrug approach in the era of bacterial resistance is targeting resistant bacteria by developing prodrugs that require bacterium-specific enzymes to release the active drug. In this article, we review the up-to-date implementation of prodrugs to develop medications that are active against drug-resistant bacteria. Keywords: prodrugs; biotransformation; targeting; β-lactam antibiotics; β-lactamases; pathogens; resistance 1. Introduction Nowadays, the issue of pathogens resistant to drugs and the urgent need for new compounds that are capable of eradicating these pathogens are well known and understood.
    [Show full text]
  • Perspectives in Antimicrobial Agents What Its All About ?
    Perspectives in antimicrobial agents Paul M. Tulkens, MD, PhD 1 Isabelle Huys, PharmD, PhD 2 1 Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium; 2 Onderzoekscentrum voor Farmaceutische Zorg en Farmaco-economie Departement Farmaceutische en Farmacologische Wetenschappen Katholieke Universiteit Leuven, Leuven, Belgium 1/6/2012 ESCP International Workshop "Patients, Infections and the Clinical Pharmacist" 1 What its all about ? • Is there a crisis in antibiotic research and development ? • What has been introduced recently ? • What is in the pipeline ? • What are the hurdles ? • Towards a really new approach ? 1/6/2012 ESCP International Workshop "Patients, Infections and the Clinical Pharmacist" 2 The antibiotic crisis * 1. Resistance * A pictorial view using 4 paintings of Van Gogh (who stayed briefly in Belgium when moving from Holland to France) and with selected Belgian and International data… 1/6/2012 ESCP International Workshop "Patients, Infections and the Clinical Pharmacist" 3 Are antibiotics following a path to madness ? discovery in soil bacteria and fungi 1928 - … 1/6/2012 ESCP International Workshop "Patients, Infections and the Clinical Pharmacist" 4 Are antibiotics following a path to madness ? and then we all saw the blooming tree of semi- synthetic and totally synthetic antibiotics 1950 – 1980 … 1/6/2012 ESCP International Workshop "Patients, Infections and the Clinical Pharmacist" 5 Are antibiotics following a path to madness ? and the US General Surgeon told us that the fight was over 1970 … 1/6/2012 ESCP International Workshop "Patients, Infections and the Clinical Pharmacist" 6 Are antibiotics following a path to madness ? But … 2012 … 1/6/2012 ESCP International Workshop "Patients, Infections and the Clinical Pharmacist" 7 Extent of resistance of P.
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • Surveillance of Iclaprim Activity: in Vitro Susceptibility of Gram-Positive Skin Infection Pathogens Collected from 2015 to 2016 from North America and Europe
    Diagnostic Microbiology and Infectious Disease 93 (2019) 154–158 Contents lists available at ScienceDirect Diagnostic Microbiology and Infectious Disease journal homepage: www.elsevier.com/locate/diagmicrobio Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe David B Huang a,⁎, Sophie Magnet f, Stefania De Angelis f, Thomas L Holland d, Thomas M File Jr b, Matthew Dryden c,G.RalphCoreyd, Antoni Torres e,MarkHWilcoxg a Motif BioSciences, New York, NY b Summa Health, Akron, OH c Department of Microbiology and Infection, Hampshire Hospitals NHS Foundation Trust, UK d Duke University Medical Center, Durham, NC e Department of Pulmonology, Hospital Clinic of Barcelona, University of Barcelona, Institut D'investigacions August Pi I Sunyer, and Centro de Investigación Biomedica En Red-Enfermedades Respiratorias, Barcelona, Spain f IHMA, Monthey, Switzerland g Leeds Teaching Hospitals & University of Leeds, Leeds, UK article info abstract Article history: Iclaprim is a diaminopyrimidine, which inhibits bacterial dihydrofolate reductase, and surveillance data prior to Received 4 December 2017 2006 suggested that iclaprim was active against Gram-positive pathogens including emerging drug-resistant Received in revised form 6 June 2018 pathogens. In an era of increasing antimicrobial resistance, we undertook testing iclaprim and comparators Accepted 4 September 2018 against 931 Gram-positive clinical isolates from the United States and Europe collected between 2015 and Available online 10 September 2018 2016. Susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Minimum inhibitory concentration (MIC) interpretations were based on CLSI and European Committee Keywords: Iclaprim on Antimicrobial Susceptibility Testing criteria.
    [Show full text]
  • Challenges of Antibacterial Discovery Lynn L
    CLINICAL MICROBIOLOGY REVIEWS, Jan. 2011, p. 71–109 Vol. 24, No. 1 0893-8512/11/$12.00 doi:10.1128/CMR.00030-10 Copyright © 2011, American Society for Microbiology. All Rights Reserved. Challenges of Antibacterial Discovery Lynn L. Silver* LL Silver Consulting, LLC, 955 S. Springfield Ave., Unit C403, Springfield, New Jersey 07081 INTRODUCTION .........................................................................................................................................................72 The Discovery Void...................................................................................................................................................72 Class Modifications versus Novel Classes.............................................................................................................72 BACKGROUND............................................................................................................................................................72 Early Screening—a Brief and Biased Philosophical History .............................................................................72 The Rate-Limiting Steps of Antibacterial Discovery ...........................................................................................74 The Multitarget Hypothesis ....................................................................................................................................74 ANTIBACTERIAL RESISTANCE ..............................................................................................................................75
    [Show full text]
  • Iclaprim Exhibited Good Activity Against Many Strains of E. Coli, K
    E-909 Antimicrobial activity of a novel dihydrofolate reductase, iclaprim, tested against clinical strains of Enterobacteriaceae: results from the International Study of Iclaprim Susceptibility (ISIS) 1 1 2 2 1 , T.R. Fritsche , K. Islam , S. Hawser , H. S. Sader H.S. Sader MD, PhD R.N. Jones Director, International Surveillance Programs, JMI Laboratories 1JMI Laboratories, North Liberty, Iowa, USA; 2Arpida AG, Reinach, Switzerland 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa, 52317, USA Phone: +1 (319) 665-3370 Fax: +1 (319) 665-3371 e-mail: [email protected] Iclaprim is a novel dihydrofolate reductase (DFHR) inhibitor belonging to the diaminopyrimidine Table 1. Activity of iclaprim and comparator agents tested against Enterobacteriaceae class of antibiotics for which trimethoprim (TMP) is the most well-known representative. TMP from the USA and Europe. CONCLUSIONS ABSTRACT is frequently used in combination with sulfamethoxazole (SMX) and this combination has Organism (no.tested)/ % susceptible/ MIC MIC Range been used in clinical practice for almost five decades. SMX is highly synergistic with TMP as Antimicrobial agent 50 90 resistanta Iclaprim exhibited good activity against many strains of E. coli, Background: Iclaprim (ICL) is a diaminopyrimidine compound for IV E. coli (107) a result of inhibition of two sequential enzymes in the folate pathway, thereby enhancing the K. pneumoniae and Enterobacter spp. with an overall MIC50 and PO use, with expanded activity against Gram-positive and Iclaprim 2 >8 0.25–>8 - / -b potency and bactericidal activity as well as reducing the potential for resistance development. against the Enterobacteriaceae species in this study of 2 μg/mL.
    [Show full text]